GoldBamboo.com - Knowledge is strong medicine
  

Home Stimulation for Brain-Asphyxiated Infants - Article


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:






Hypoxia

 




Clinical Trial: Home Stimulation for Brain-Asphyxiated Infants

This study is currently recruiting patients.

Sponsored by: National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institute of Child Health and Human Development (NICHD)

Purpose

This study examines the potential benefits of a home stimulation program to treat infants who have suffered from brain asphyxiation (lack of oxygen). The program involves one year of stimulatory activities. Progress will be evaluated through neurological and behavioral exams.

Condition Treatment or Intervention Phase
Hypoxia, Brain
Hypoxia-Ischemia, Brain
 Behavior: Infant stimulation
Phase II

MedlinePlus related topics:  Stroke

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study

Official Title: Neuroplasticity of Brain-Asphyxiated Infants: Efficacy of Intervention

Further Study Details: 

Expected Total Enrollment:  120

Study start: September 1999;  Expected completion: August 2004

Although the incidence of brain injury in infants is only 2 to 5 per 1000 births, the legal and medical costs, the developmental delays, and the impact on the family are profound. Twenty to 30% of survivors of brain injury have some long-term neurologic sequelae.

This randomized controlled trial will enroll 120 term and near-term neonates with a history of asphyxia to 1-year of a standard follow-up program (provided by the Los Angeles Regional Centers) or a home-based intervention program (Utah State University's Developmental Curriculum and Monitoring System, CAMS). The experimental intervention will include individualized cognitive/neuromotor stimulation given by the child's parents under the guidance of public health nurses. Following the intervention, measures will be used to determine functional capacity (Bayley II scale and neurologic examination), behavioral outcomes (HOME and NCAST by developmental specialists), and maternal outcomes (including parent-infant interaction and perceived stress). Infants will be assessed after the 1-year intervention by psychologists and physicians masked to the intervention. Functional MRI brain studies will be conducted at discharge and 18 months of age at UCLA to assess qualitative and quantitative sensorimotor representation. Secondary outcomes include care stress and social support as reported by parents, and demographics and medical factors obtained from the hospital records.

Eligibility

Ages Eligible for Study:  up to  1 Month,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

All of the following criteria must be met:

  • Gestation age (GA) at birth >= 28 weeks
  • Discharged to home care with parent or other guardian who has legal authority to give informed consent
  • Greater than 10th percentile for GA at birth using the scales according to Lubchenco, Hansman, and Boyd from Pediatrics 1966 volume 37 and Battaglia and Lubchenco in the Journal of Pediatrics 1967 volume 71
  • Jewelry in pierced body parts can be removed
  • Mothers > 17 years old
  • Recruited within 60 days of EDC (estimated date of conception)

Two or more of the following must be met:

  • Intrapartum distress as determined by placental abruption, thick meconium staining of amniotic fluid, sustained fetal bradycardia of heart rate < 100 beats/min, or late or absent heart rate variability
  • Profound metabolic or mixed academia as determined by umbilical artery pH < 7.0, base deficit of > 10 mEq/L or pH < 7.1 and base excess greater than 14 mmol/L within 72 hours of birth, Apgar score < 5 at 5 minutes or beyond, or need for positive pressure ventilation resuscitation for > 1 min after birth
  • Neonatal neurological manifestations such as seizures during hospital stay, lethargy, hypotonia or hypertonia, stupor, flaccidity, or decerebration
  • Multiple organ system dysfunction
  • Abnormal EEG, CT scan, or MRI consistent with hypoxic or ischemic brain insult

Exclusion Criteria:

  • Infants of substance abusing mothers (ISAM)
  • Intrauterine growth retardation (IUGR)
  • Infants requiring extracorporeal membrane oxygenation (ECMO) in the neonatal period
  • Hearing or visual impairment
  • Congenital cyanotic heart disease with cyanosis and requiring PGE infusion. Children with minimum cardiac structural anomalies (e.g., PDA or VSD or peripheral pulmonary stenosis) will not be excluded from the study.
  • Congenital abnormalities of the central nervous system such as congenital hydrocephalus
  • Grade IV intraventicular hemorrhage requiring ventriculo-peritoneal shunt (VP shunt)
  • Trisomy 13, 18, or 21, or Fragile X
  • Metabolic encephalopathy from inborn errors of metabolism (e.g. PKU, OTC)
  • Metal or wire mesh implants, pacemaker implants, cochlear implants, orthopedic surgical wires or implants
  • Status epilepticus
  • Ventilator dependent at discharge
  • Infectious meningitis
  • Encephalitis with radiological evidence of severe cortical or severe hemispheric destruction
  • Silastic catheters, broviacs, or Hickman port home TPA
  • Infants who may not be available for the duration of the study
  • Any infant who in the opinion of investigator has no potential to benefit from the intervention (e.g., children with prenatal herpes meningitis, severe cortical destruction, mother does not follow up with the intervention or with the follow-up appointments)

Location and Contact Information

Meena Garg, MD      310-794-8864    mgarg@mednet.ucla.edu

California
      University of California at Los Angeles, Los Angeles,  California,  90095,  United States; Recruiting
Meena Garg, MD  310-794-8864    mgarg@mednet.ucla.edu 

Study chairs or principal investigators

Meena Garg, MD,  Principal Investigator,  University of California at Los Angeles   

More Information

Click here for more information on the National Institute of Child Health and Human Development clinical trials.

Study ID Numbers:  NICHD-0115; 1R01 HD38600-01
Record last reviewed:  March 2003
Last Updated:  October 13, 2004
Record first received:  November 21, 2000
ClinicalTrials.gov Identifier:  NCT00006516
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Hypoxia.

November 29, 2009



Page Updated: October 3, 2005
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.